ETON vs. CELU, ASRT, ANIX, RNAC, SPRO, VACC, BRNS, DMAC, RVPH, and CMRX
Should you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Celularity (CELU), Assertio (ASRT), Anixa Biosciences (ANIX), Cartesian Therapeutics (RNAC), Spero Therapeutics (SPRO), Vaccitech (VACC), Barinthus Biotherapeutics (BRNS), DiaMedica Therapeutics (DMAC), Reviva Pharmaceuticals (RVPH), and Chimerix (CMRX). These companies are all part of the "pharmaceutical preparations" industry.
Eton Pharmaceuticals (NASDAQ:ETON) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.
In the previous week, Celularity had 1 more articles in the media than Eton Pharmaceuticals. MarketBeat recorded 3 mentions for Celularity and 2 mentions for Eton Pharmaceuticals. Celularity's average media sentiment score of 1.58 beat Eton Pharmaceuticals' score of 0.60 indicating that Celularity is being referred to more favorably in the news media.
Eton Pharmaceuticals has a net margin of -2.96% compared to Celularity's net margin of -1,226.72%. Celularity's return on equity of 30.79% beat Eton Pharmaceuticals' return on equity.
Eton Pharmaceuticals received 75 more outperform votes than Celularity when rated by MarketBeat users. Likewise, 61.94% of users gave Eton Pharmaceuticals an outperform vote while only 42.11% of users gave Celularity an outperform vote.
Celularity has lower revenue, but higher earnings than Eton Pharmaceuticals.
Eton Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 166.67%. Given Eton Pharmaceuticals' higher possible upside, analysts clearly believe Eton Pharmaceuticals is more favorable than Celularity.
27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 13.2% of Eton Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Eton Pharmaceuticals has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Comparatively, Celularity has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.
Summary
Eton Pharmaceuticals beats Celularity on 8 of the 15 factors compared between the two stocks.
Get Eton Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Eton Pharmaceuticals Competitors List
Related Companies and Tools